Research & Reviews: Medical and Clinical Oncology

Melanoma Genetics and Molecular Pathways: Understanding the Genetic Drivers of Determined Skin Cancer

Rusell Keller*

Department of General Surgery, University of Odense, Odense, Denmark

Commentary

Received: 27-Dec-2024, Manuscript No. MCO-24-156760; **Editor assigned:** 01-Jan-2025, PreQC No. MCO-24-156760 (PQ); **Reviewed:** 15-Jan-2025, QC No. MCO-24-156760; **Revised:** 07-Mar-2025, Manuscript No. MCO-24-156760 (R); **Published:** 14-Mar-2025, DOI: 10.4172/medclinoncol.9.01.005.

***For Correspondence:**
Rusell Keller, Department of General Surgery, University of Odense, Odense, Denmark,

E-mail: keller@tscchr.de

Citation: Keller R. Melanoma Genetics and Molecular Pathways: Understanding the Genetic Drivers of Determined Skin Cancer. Med Clin Oncol. 2025;09:005.

DESCRIPTION

Melanoma, a highly aggressive form of skin cancer, arises from melanocytes, the pigment-producing cells in the skin. Despite being less common than other types of skin cancer, melanoma is responsible for a significant number of skin cancer-related deaths due to its propensity for metastasis. The genetic and molecular mechanisms underlying melanoma are complex and multifactorial, involving a series of genetic mutations and alterations in molecular signaling pathways that promote tumorigenesis. Over the years, advancements in genomics and molecular biology have provided valuable insights into the genetic drivers and molecular pathways involved in melanoma, leading to the development of targeted therapies and improved treatment strategies.

A key factor in melanoma development is the accumulation of genetic mutations, many of which are induced by Ultraviolet (UV) radiation from sun exposure. UV radiation is a known carcinogen that causes DNA damage, resulting in mutations that can lead to the initiation and progression of melanoma. Among the most frequently mutated genes in melanoma are those involved in the MAPK (mitogen-activated protein kinase) pathway, particularly the BRAF gene. Mutations in BRAF, especially the V600E mutation, are present in approximately 50% of melanomas and are associated with uncontrolled cell growth and survival. This mutation leads to the activation of the MAPK pathway, which regulates key cellular processes such as proliferation, differentiation, and apoptosis. Targeted inhibitors of BRAF, such as vemurafenib and dabrafenib, have shown efficacy in treating melanoma patients with BRAF mutations, significantly improving survival outcomes.

In addition to BRAF mutations, mutations in other genes, including NRAS, KIT, and TP53, have also been implicated in melanoma pathogenesis. NRAS mutations occur in approximately 15%-20% of melanomas and lead to the activation of the RAS-RAF-MEK-ERK signaling pathway, which similarly promotes tumorigenesis. KIT mutations, while less common, are often found in melanoma cases associated with mucosal or acral lentiginous subtypes. TP53, a well-known tumor suppressor gene, is frequently mutated in melanoma, contributing to the loss of genomic integrity and facilitating the development of resistance to therapy.

The molecular pathways that drive melanoma are not limited to mutations in individual genes but also involve complex interactions between signaling networks that regulate key cellular functions. The MAPK pathway is central to melanoma development and progression, but other signaling pathways also play crucial roles. One of these is the PI3K-AKT-mTOR pathway, which is involved in cell survival, metabolism, and resistance to chemotherapy. Mutations or amplifications in genes such as PTEN, which negatively regulates the PI3K pathway, can lead to constitutive activation of this pathway and contribute to melanoma progression. Targeting the PI3K-AKT-mTOR pathway with specific inhibitors has shown promise in preclinical studies, but clinical efficacy remains to be fully established.

CONCLUSION

Melanoma is driven by a complex interplay of genetic mutations and molecular signaling pathways that promote tumorigenesis and resistance to treatment. Advances in genomics and molecular biology have provided invaluable insights into the genetic drivers of melanoma and have led to the development of targeted therapies and immunotherapies that have improved survival rates for many patients. However, the challenges of resistance and metastatic disease highlight the need for continued research to uncover new therapeutic targets and strategies to further improve outcomes for melanoma patients.